Bernstein L H, Frank M S, Brandt L J, Boley S J
Gastroenterology. 1980 Aug;79(2):357-65.
The effect of metronidazole was studied in 21 consecutive patients with chronic unremitting perineal Crohn's disease. Drainage, erythema, and induration diminished dramatically in all patients, and complete healing was obtained in 10 of 18 patients maintained on therapy. Five others have shown advanced healing; in 2 patients the inflammation is improved, but healing is minimal. Side effects of metallic taste, dark urine, and mild gastrointestinal upset occurred in many patients. However, the dosage had to be decreased in only 4 patients and the drug discontinued in 1 patient, all because of peripheral neuropathy that proved to be reversible. In 2 other patients, metronidazole was discontinued because of poor compliance. If further experience corroborates this prompt and striking response in patients with extreme, disabling, and otherwise unmanageable disease, metronidazole will play an important role in the therapy of perineal Crohn's disease.
对21例连续性慢性顽固性会阴克罗恩病患者研究了甲硝唑的疗效。所有患者的引流、红斑和硬结均显著减轻,在接受治疗的18例患者中,10例实现了完全愈合。另有5例显示有明显愈合;2例患者炎症有所改善,但愈合程度极小。许多患者出现了金属味、尿液变黑和轻度胃肠道不适等副作用。然而,仅4例患者需要减少剂量,1例患者停药,均是因为外周神经病变,而该病变被证明是可逆的。另外2例患者因依从性差而停用甲硝唑。如果进一步的经验证实这种对病情严重、致残且难以处理的疾病有迅速而显著的反应,那么甲硝唑将在会阴克罗恩病的治疗中发挥重要作用。